---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205079"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:29:39.448811+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Climb Bio reports positive SC formulation data; ITP data June 2026, pMN/SLE Q4 2026

## Summary
- Topline Phase 1 SC data: robust B-cell depletion similar to IV; generally safe and well-tolerated.
- Fast Track Designation received for primary membranous nephropathy (pMN).
- Initial ITP Phase 1b/2a data from low-dose cohort expected June 2026.
- Initial pMN Phase 2 and SLE Phase 1b data expected Q4 2026.
- Budoprutug is an anti-CD19 mAb targeting B-cell mediated diseases; trials enrolling to plan.

## SEC filing metadata
- accession: 0001193125-26-205079
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526205079/0001193125-26-205079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526205079/d127757d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205079
- JSON: https://secwatch.observer/filing/0001193125-26-205079.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.